Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1983 Jul;53(1):122–132.

Difference in effect of single immunosuppressive agents (cyclophosphamide, CCNU, 5-FU) on peripheral blood immune cell parameters and central nervous system immunoglobulin synthesis rate in patients with multiple sclerosis.

W W Shih, R W Baumhefner, W W Tourtellotte, C M Haskell, E L Korn, J L Fahey
PMCID: PMC1535539  PMID: 6603303

Abstract

Cyclophosphamide (CY), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 5-fluorouracil (5-FU) were given in single course schedules to chronic progressive multiple sclerosis (MS) patients clinically stable for 6 months. The following peripheral immune cellular parameters were measured before, during and after each drug administration: white blood count (WBC), polymorphonuclear count (PMN), lymphocyte count, percentage of T cells, T cell response to phytohaemagglutinin (PHA), percentage of B cells, percentage of cells bearing receptors for the Fc portion of immunoglobulin (% FcR cells), killer (K) cell activity defined by antibody-dependent cellular cytotoxicity (ADCC), and natural killer (NK) cell activity. Central nervous system (CNS) immunoglobulin G (IgG) synthesis was also measured. The patients were followed carefully by both quantitative and qualitative methods for any change in their neurologic condition. Selective reduction in NK activity was observed with CY and 5-FU while no significant alteration was seen in %FcR cells and K activity. CY differed from 5-FU in reducing lymphocyte count and B cell percentage while 5-FU decreased the percentage of T cells. CCNU, but not the other drugs, reduced T cell proliferative response to PHA. In addition, CCNU, which is known to penetrate well into the nervous system, caused a modest reduction in CNS IgG synthesis, while 5-FU had an uncertain effect. Clinically the patients were unchanged or continued to progress in their disability. The results suggest an independence of the CNS immune from the systemic immune system in MS in response to many immunosuppressive drugs.

Full text

PDF
122

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abb J., Netzel B., Rodt H. V., Thierfelder S. Autologous bone marrow grafts in dogs treated with lethal doses of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Cancer Res. 1978 Jul;38(7):2157–2159. [PubMed] [Google Scholar]
  2. Barbers R. G., Shih W. W., Saxon A. In vitro depression of human lymphocyte mitogen response (phytohaemagglutinin) by asbestos fibres. Clin Exp Immunol. 1982 Jun;48(3):602–610. [PMC free article] [PubMed] [Google Scholar]
  3. Benczur M., Petrányl G. G., Pálffy G., Varga M., Tálas M., Kotsy B., Földes I., Hollán S. R. Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor. Clin Exp Immunol. 1980 Mar;39(3):657–662. [PMC free article] [PubMed] [Google Scholar]
  4. Bloom B. R. Immunological changes in multiple sclerosis. Nature. 1980 Sep 25;287(5780):275–276. doi: 10.1038/287275a0. [DOI] [PubMed] [Google Scholar]
  5. Bourke R. S., West C. R., Chheda G., Tower D. B. Kinetics of entry and distribution of 5-fluorouracil in cerebrospinal fluid and brain following intravenous injection in a primate. Cancer Res. 1973 Jul;33(7):1735–1746. [PubMed] [Google Scholar]
  6. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77–89. [PubMed] [Google Scholar]
  7. Carter S. K., Schabel F. M., Jr, Broder L. E., Johnston T. P. 1,3-bis(2-chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review. Adv Cancer Res. 1972;16:273–332. doi: 10.1016/s0065-230x(08)60343-7. [DOI] [PubMed] [Google Scholar]
  8. Cendrowski W., Niedzielska K. Lymphocyte transformation induced in vitro by PHA and PPD in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1970 Feb;33(1):92–94. doi: 10.1136/jnnp.33.1.92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chabner B. A., Myers C. E., Oliverio V. T. Clinical pharmacology of anticancer drugs. Semin Oncol. 1977 Jun;4(2):165–191. [PubMed] [Google Scholar]
  10. Clements P. J., Yu D. T., Levy J., Paulus H. E., Barnett E. V. Effects of cyclophosphamide on B- and T-lymphocytes in rheumatoid arthritis. Arthritis Rheum. 1974 Jul-Aug;17(4):347–353. doi: 10.1002/art.1780170403. [DOI] [PubMed] [Google Scholar]
  11. Djeu J. Y., Heinbaugh J. A., Vieira W. D., Holden H. T., Herberman R. B. The effect of immunopharmacological agents on mouse natural cell-mediated cytotoxicity and on its augmentation by poly I:C. Immunopharmacology. 1979 Jun;1(3):231–244. doi: 10.1016/0162-3109(79)90040-7. [DOI] [PubMed] [Google Scholar]
  12. Drachman D. A., Paterson P. Y., Schmidt R. T., Spehlmann R. F. Cyclophosphamide in exacerbations of multiple sclerosis. Therapeutic trial and a strategy for pilot drug studies. J Neurol Neurosurg Psychiatry. 1975 Jun;38(6):592–597. doi: 10.1136/jnnp.38.6.592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Duncan J. H., Colvin O. M., Fenselau C. Mass spectrometric study of the distribution of cyclophosphamide in humans. Toxicol Appl Pharmacol. 1973 Feb;24(2):317–323. doi: 10.1016/0041-008x(73)90151-8. [DOI] [PubMed] [Google Scholar]
  14. Fauci A. S. Immunosuppressive and anti-inflammatory effects of glucocorticoids. Monogr Endocrinol. 1979;12:449–465. doi: 10.1007/978-3-642-81265-1_24. [DOI] [PubMed] [Google Scholar]
  15. Ghaffar A., Lichter W., Wellham L. L., Sigel M. M. Effect of anticancer chemotherapeutic agents on immune reactions of mice. I. Comparison of two nitrosoureas: 1,3-bis(2-chloroethyl)-1-nitrosourea and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. J Natl Cancer Inst. 1978 Jun;60(6):1483–1487. doi: 10.1093/jnci/60.6.1483. [DOI] [PubMed] [Google Scholar]
  16. Graul E. H., Schaumlöffel E., Hundeshagen H., Wilmanns H., Simon G. Metabolism of radioactive cyclophosphamide. Animal tests and clinical studies. Cancer. 1967 May;20(5):896–899. doi: 10.1002/1097-0142(1967)20:5<896::aid-cncr2820200551>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  17. Herberman R. B., Ortaldo J. R. Natural killer cells: their roles in defenses against disease. Science. 1981 Oct 2;214(4516):24–30. doi: 10.1126/science.7025208. [DOI] [PubMed] [Google Scholar]
  18. Hommes O. R., Prick J. J., Lamers K. J. Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone. Clin Neurol Neurosurg. 1975;78(1):59–72. doi: 10.1016/s0303-8467(75)80007-2. [DOI] [PubMed] [Google Scholar]
  19. Iivanainen M. V. The significance of abnormal immune responses in patients with multiple sclerosis. J Neuroimmunol. 1981 Jun;1(2):141–172. doi: 10.1016/0165-5728(81)90040-0. [DOI] [PubMed] [Google Scholar]
  20. Imbach J. L., Montero J. L., Moruzzi A., Serrou B., Chenu E., Hayat M., Mathe G. The oncostatic and immunosuppressive action of new nitrosourea derivatives containing sugar radicals. Biomedicine. 1975 Dec 20;23(10):410–413. [PubMed] [Google Scholar]
  21. Kleinhenz M. E., Ellner J. J., Spagnuolo P. J., Daniel T. M. Suppression of lymphocyte responses by tuberculous plasma and mycobacterial arabinogalactan. Monocyte dependence and indomethacin reversibility. J Clin Invest. 1981 Jul;68(1):153–162. doi: 10.1172/JCI110231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kurtzke J. F. Neurologic impairment in multiple sclerosis and the disability status scale. Acta Neurol Scand. 1970;46(4):493–512. doi: 10.1111/j.1600-0404.1970.tb05808.x. [DOI] [PubMed] [Google Scholar]
  23. Lichtenstein A., Zighelboim J., Dorey F., Brossman S., Fahey J. L. Comparison of immune derangements in patients with different malignancies. Cancer. 1980 Apr 15;45(8):2090–2095. doi: 10.1002/1097-0142(19800415)45:8<2090::aid-cncr2820450816>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  24. Lisak R. P. Multiple sclerosis: immunologic aspects. Ann Clin Lab Sci. 1975 Sep-Oct;5(5):324–329. [PubMed] [Google Scholar]
  25. Nordman E., Saarimaa H., Toivanen A. The influence of 5-fluorouracil on cellular and humoral immunity in cancer patients. Cancer. 1978 Jan;41(1):64–69. doi: 10.1002/1097-0142(197801)41:1<64::aid-cncr2820410111>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  26. Oehler J. R., Herberman R. B. Natural cell-mediated cytotoxicity in rats. III. Effects of immunopharmacologic treatments on natural reactivity and on reactivity augmented by polyinosinic-polycytidylic acid. Int J Cancer. 1978 Feb 15;21(2):221–229. doi: 10.1002/ijc.2910210214. [DOI] [PubMed] [Google Scholar]
  27. Raine C. S. The etiology and pathogenesis of multiple sclerosis: recent developments. Pathobiol Annu. 1977;7:347–384. [PubMed] [Google Scholar]
  28. Santoli D., Koprowski H. Mechanisms of activation of human natural killer cells against tumor and virus-infected cells. Immunol Rev. 1979;44:125–163. doi: 10.1111/j.1600-065x.1979.tb00269.x. [DOI] [PubMed] [Google Scholar]
  29. Shih W. W., Ellison G. W., Myers L. W., Durkos-Smith D., Fahey J. L. Locus of selective depression of human natural killer cells by azathioprine. Clin Immunol Immunopathol. 1982 Jun;23(3):672–681. doi: 10.1016/0090-1229(82)90330-0. [DOI] [PubMed] [Google Scholar]
  30. Simpson J. F., Tourtellotte W. W., Kokmen E., Parker J. A., Itabashi H. H. Fluorescent protein tracing in multiple sclerosis brain tissue. Arch Neurol. 1969 Apr;20(4):373–377. doi: 10.1001/archneur.1969.00480100049007. [DOI] [PubMed] [Google Scholar]
  31. Tourtellotte W. W., Baumhefner R. W., Potvin A. R., Ma B. I., Potvin J. H., Mendez M., Syndulko K. Multiple sclerosis de novo CNS IgG synthesis: effect of ACTH and corticosteroids. Neurology. 1980 Nov;30(11):1155–1162. doi: 10.1212/wnl.30.11.1155. [DOI] [PubMed] [Google Scholar]
  32. Tourtellotte W. W., Ma B. I. Multiple sclerosis: the blood-brain-barrier and the measurement of de novo central nervous system IgG synthesis. Neurology. 1978 Sep;28(9 Pt 2):76–83. doi: 10.1212/wnl.28.9_part_2.76. [DOI] [PubMed] [Google Scholar]
  33. Turk J. L., Poulter L. W. Selective depletion of lymphoid tissue by cyclophosphamide. Clin Exp Immunol. 1972 Feb;10(2):285–296. [PMC free article] [PubMed] [Google Scholar]
  34. Winchester R. J., Fu S. M., Hoffman T., Kunkel H. G. IgG on lymphocyte surfaces; technical problems and the significance of a third cell population. J Immunol. 1975 Apr;114(4):1210–1212. [PubMed] [Google Scholar]
  35. Winkelstein A., Mikulla J. M., Nankin H. R., Pollock B. H., Stolzer B. L. Mechanisms of immunosuppression: effects of cyclophosphamide on lymphocytes. J Lab Clin Med. 1972 Oct;80(4):506–513. [PubMed] [Google Scholar]
  36. YAHR M. D., KABAT E. A. Cerebrospinal fluid and serum gamma globulin levels in multiple sclerosis: changes induced by large doses of prednisone. Trans Am Neurol Assoc. 1957;82ND:115–119. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES